FDA Avandia Hearing Update – Committee Votes Increased Risk of CV events, No Increase in Mortality

After almost two days of rigorous debate, the time for the FDA vote on the fate of Avandia is upon us.

The 33 member FDA advisory committee on rosiglitizone has voted that despite causing increase risk in cardiovascular events Avandia does not increase risk of death.

On the Question of Avendia (rosiglitazone) increases risk of ischemic CV events in patients with type II diabetes:

 

Increases Risk

Does Not Increase Risk

Data Inconclusive

Avandia vs other glycemic agents (non TZD’s)

 

18

6

9

CV Events

Avandia vs Actos

21

4

8

 

On the question of Avandia (rosiglitazone) increases the risk of mortality in patients with type II diabetes:

 

Increases Mortality

Does Not Increase Mortality

Data Inconclusive

Avandia vs other glycemic agents (Non TZD’s)

 

0

20

12

CV Events

Avandia vs Actos

7

12

14

 

Given the lack of evidence that rosiglitizone increases the risk of cardiovascular death, it is highly unlikely that FDA advisory committee will vote in favor of pulling Avandia from the market.

 

avandiafood and drug adminstrationNEW
Comments (0)
Add Comment